Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1399) 1399
science & technology (1316) 1316
life sciences & biomedicine (1270) 1270
female (1047) 1047
oncology (1000) 1000
topotecan - administration & dosage (980) 980
topotecan (941) 941
middle aged (649) 649
chemotherapy (641) 641
biological and medical sciences (625) 625
medical sciences (623) 623
male (605) 605
adult (588) 588
aged (586) 586
antineoplastic combined chemotherapy protocols - therapeutic use (575) 575
antineoplastic agents (508) 508
pharmacology. drug treatments (494) 494
topotecan - adverse effects (399) 399
ovarian neoplasms - drug therapy (337) 337
topotecan - therapeutic use (331) 331
treatment outcome (326) 326
cancer (321) 321
antineoplastic agents - administration & dosage (319) 319
drug administration schedule (317) 317
antineoplastic agents - therapeutic use (302) 302
animals (289) 289
tumors (260) 260
pharmacology & pharmacy (248) 248
antineoplastic combined chemotherapy protocols - adverse effects (243) 243
lung neoplasms - drug therapy (228) 228
topotecan - pharmacokinetics (228) 228
neoplasm recurrence, local - drug therapy (221) 221
ovarian cancer (221) 221
camptothecin - analogs & derivatives (216) 216
dose-response relationship, drug (213) 213
antineoplastic agents - adverse effects (204) 204
paclitaxel - administration & dosage (202) 202
cisplatin - administration & dosage (195) 195
mice (189) 189
antineoplastic combined chemotherapy protocols - administration & dosage (187) 187
infusions, intravenous (177) 177
aged, 80 and over (176) 176
carboplatin - administration & dosage (173) 173
antineoplastic agents - pharmacokinetics (164) 164
topotecan - pharmacology (162) 162
neoplasms - drug therapy (160) 160
adolescent (154) 154
child (154) 154
child, preschool (153) 153
care and treatment (151) 151
drug resistance, neoplasm (144) 144
etoposide - administration & dosage (140) 140
obstetrics & gynecology (140) 140
topoisomerase i inhibitors (139) 139
disease-free survival (138) 138
survival rate (136) 136
cell line, tumor (130) 130
neoplasm staging (129) 129
research (129) 129
ovarian neoplasms - pathology (128) 128
medicine & public health (127) 127
survival analysis (126) 126
antineoplastic agents - pharmacology (123) 123
hematology (122) 122
camptothecin - administration & dosage (120) 120
retrospective studies (118) 118
carcinoma, small cell - drug therapy (113) 113
combined modality therapy (113) 113
administration, oral (112) 112
deoxycytidine - analogs & derivatives (109) 109
doxorubicin - administration & dosage (109) 109
prognosis (106) 106
infant (104) 104
clinical trials (101) 101
antimitotic agents (100) 100
drug therapy (99) 99
deoxycytidine - administration & dosage (98) 98
hematology, oncology and palliative medicine (98) 98
lung neoplasms - pathology (98) 98
analysis (91) 91
cyclophosphamide - administration & dosage (89) 89
pediatrics (89) 89
pharmacokinetics (89) 89
toxicity (89) 89
camptothecin - therapeutic use (88) 88
maximum tolerated dose (88) 88
follow-up studies (87) 87
neutropenia - chemically induced (87) 87
paclitaxel (87) 87
cisplatin (83) 83
topoisomerase i inhibitors - administration & dosage (82) 82
irinotecan (81) 81
lung cancer (79) 79
pharmacology/toxicology (79) 79
recurrence (78) 78
carboplatin (77) 77
etoposide (77) 77
cancer therapies (75) 75
gynecology. andrology. obstetrics (75) 75
drug synergism (73) 73
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1618) 1618
French (12) 12
Japanese (12) 12
Chinese (11) 11
German (4) 4
Hungarian (4) 4
Italian (4) 4
Polish (3) 3
Portuguese (3) 3
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pharmacotherapy for recurrent ovarian cancer: Current status and future perspectives
by Matsumoto, Koji and Onda, Takashi and Yaegashi, Nobuo
Japanese journal of clinical oncology, ISSN 0368-2811, 05/2015, Volume 45, Issue 5, pp. 408 - 410
Chemo-gynecology | Molecular Dx | Gynecol-med | Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Folic Acid - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Vinca Alkaloids - administration & dosage | Benzimidazoles - administration & dosage | Doxorubicin - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Antimetabolites, Antineoplastic - pharmacology | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Everolimus | Ovarian Neoplasms - drug therapy | Recombinant Fusion Proteins - administration & dosage | Doxorubicin - administration & dosage | Sirolimus - analogs & derivatives | Folic Acid - analogs & derivatives | Phthalazines - administration & dosage | Pyrimidines - administration & dosage | Deoxycytidine - administration & dosage | Angiogenesis Inhibitors - pharmacology | Carboplatin - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors | Polyethylene Glycols - administration & dosage | Sirolimus - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Nivolumab | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Topotecan - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study
by Pignata, Sandro and Scambia, Giovanni and Bologna, Alessandra and Signoriello, Simona and Vergote, Ignace B and Wagner, Uwe and Lorusso, Domenica and Murgia, Viviana and Sorio, Roberto and Ferrandina, Gabriella and Sacco, Cosimo and Cormio, Gennaro and Breda, Enrico and Cinieri, Saverio and Natale, Donato and Mangili, Giorgia and Pisano, Carmela and Cecere, Sabrina Chiara and Di Napoli, Marilena and Salutari, Vanda and Raspagliesi, Francesco and Arenare, Laura and Bergamini, Alice and Bryce, Jane and Daniele, Gennaro and Piccirillo, Maria Carmela and Gallo, Ciro and Perrone, Francesco
Journal of clinical oncology, ISSN 0732-183X, 10/2017, Volume 35, Issue 29, pp. 3347 - 3353
Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ovarian Neoplasms - mortality | Early Termination of Clinical Trials | Time Factors | Dioxoles - administration & dosage | Doxorubicin - analogs & derivatives | Female | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Treatment Outcome | Tetrahydroisoquinolines - administration & dosage | Disease Progression | Polyethylene Glycols - administration & dosage | Disease-Free Survival | Topotecan - administration & dosage | Aged | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
by Pujade-Lauraine, Eric and Pujade-Lauraine, Eric and Hilpert, Felix and Hilpert, Felix and Weber, Béatrice and Weber, Béatrice and Reuss, Alexander and Reuss, Alexander and Poveda, Andres and Poveda, Andres and Kristensen, Gunnar and Kristensen, Gunnar and Sorio, Roberto and Sorio, Roberto and Vergote, Ignace and Vergote, Ignace and Witteveen, Petronella and Witteveen, Petronella and Bamias, Aristotelis and Bamias, Aristotelis and Pereira, Deolinda and Pereira, Deolinda and Wimberger, Pauline and Wimberger, Pauline and Oaknin, Ana and Oaknin, Ana and Mirza, Mansoor Raza and Mirza, Mansoor Raza and Follana, Philippe and Follana, Philippe and Bollag, David and Bollag, David and Ray-Coquard, Isabelle and Ray-Coquard, Isabelle
Journal of clinical oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Female genital diseases | Doxorubicin - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Polyethylene Glycols - adverse effects | Drug Resistance, Neoplasm | Polyethylene Glycols - therapeutic use | Organoplatinum Compounds - pharmacology | Bevacizumab | Antibodies, Monoclonal, Humanized - administration & dosage | Doxorubicin - analogs & derivatives | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Paclitaxel - adverse effects | Topotecan - adverse effects | Topotecan - therapeutic use | Paclitaxel - therapeutic use | Polyethylene Glycols - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Aged | Doxorubicin - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin’s lymphoma
by García‐Sanz, R and González‐López, T.J and Vázquez, L and Hermida, G and Graciani, I.F and San Miguel, J.F
European journal of haematology, ISSN 0902-4441, 03/2010, Volume 84, Issue 3, pp. 266 - 270
dexamethasone | refractory disease | cyclophosphamide | thalidomide | transplantation | Hodgkin's lymphoma | Cyclophosphamide | Transplantation | Dexamethasone | Refractory disease | Thalidomide | Life Sciences & Biomedicine | Hematology | Science & Technology | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Salvage Therapy | Drug Resistance, Neoplasm | Male | Transplantation, Autologous | Vinblastine - administration & dosage | Hodgkin Disease - surgery | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Organoplatinum Compounds - administration & dosage | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Deoxycytidine - administration & dosage | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Vidarabine - analogs & derivatives | Bleomycin - administration & dosage | Thalidomide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Melphalan - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Mechlorethamine - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Deoxycytidine - analogs & derivatives | Carmustine - administration & dosage | Antimitotic agents | Stem cells | Antineoplastic agents | Hodgkin's disease | Steroids | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma
by Federico, Sara M and McCarville, M. Beth and Shulkin, Barry L and Sondel, Paul M and Hank, Jacquelyn A and Hutson, Paul and Meagher, Michael and Shafer, Aaron and Ng, Catherine Y and Leung, Wing and Janssen, William E and Wu, Jianrong and Mao, Shenghua and Brennan, Rachel C and Santana, Victor M and Pappo, Alberto S and Furman, Wayne L
Clinical cancer research, ISSN 1078-0432, 11/2017, Volume 23, Issue 21, pp. 6441 - 6449
Life Sciences & Biomedicine | Oncology | Science & Technology | Drug-Related Side Effects and Adverse Reactions - blood | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Neuroblastoma - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Dacarbazine - analogs & derivatives | Killer Cells, Natural - immunology | Camptothecin - administration & dosage | Female | Child | Neoplasm Recurrence, Local - blood | Neuroblastoma - pathology | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Dacarbazine - administration & dosage | Gangliosides - antagonists & inhibitors | Interleukin-2 Receptor alpha Subunit - blood | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cell- and Tissue-Based Therapy | Gangliosides - immunology | Disease-Free Survival | Ifosfamide - administration & dosage | Neuroblastoma - drug therapy | Adolescent | Topotecan - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Interleukin-2 - blood | Toxicity | Cytotoxicity | Malignancy | Neuroblastoma | Cerebrospinal fluid | Pain | Interleukin 2 | Surgery | Myelosuppression | Children | Natural killer cells | Antibody-dependent cell-mediated cytotoxicity | Thrombocytopenia | Immune response | Cytokines | Ifosfamide | Granulocyte-macrophage colony-stimulating factor | Hypersensitivity | Etoposide | Pharmacology | Patients | Irinotecan | Cyclophosphamide | Chemotherapy | Experimental design | Monoclonal antibodies | Carboplatin | Temozolomide | Pharmacokinetics | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese
by Alex Sparreboom and Antonio C. Wolff and Ron H.J. Mathijssen and Etienne Chatelut and Eric K. Rowinsky and Jaap Verweij and Sharyn D. Baker
Journal of clinical oncology, ISSN 0732-183X, 10/2007, Volume 25, Issue 30, pp. 4707 - 4713
Life Sciences & Biomedicine | Oncology | Science & Technology | Obesity | Biological and medical sciences | Metabolic diseases | Medical sciences | Tumors | Body Mass Index | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Body Weight | Obesity - drug therapy | Area Under Curve | Body Size | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Carboplatin - administration & dosage | Cytosine - administration & dosage | Metabolic Clearance Rate | Cisplatin - administration & dosage | Obesity - metabolism | Taxoids - administration & dosage | Adolescent | Topotecan - administration & dosage | Camptothecin - administration & dosage | Dioxolanes - administration & dosage | Body Surface Area | Paclitaxel - administration & dosage | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
by Chekerov, Radoslav and Hilpert, Felix and Mahner, Sven and El-Balat, Ahmed and Harter, Philipp and De Gregorio, Nikolaus and Fridrich, Claudius and Markmann, Susanne and Potenberg, Jochem and Lorenz, Ralf and Oskay-Oezcelik, Guelten and Schmidt, Marcus and Krabisch, Petra and Lueck, Hans-Joachim and Richter, Rolf and Braicu, Elena Ioana and du Bois, Andreas and Sehouli, Jalid and Lichtenegger, Werner and Yalcinkaya, Isil and Kittner, Marion and Konwert, Ellen and Keller, Maren and Mustea, Alexander and Koensgen-Mustea, Dominique and Pietzner, Klaus and Camara, Oumar and Wimberger, Pauline and Elser, Gabriele and Polleis, Sandra and NOGGO and AGO TRIAS Investigators and NOGGO-AGO TRIAS Investigators
The lancet oncology, ISSN 1470-2045, 09/2018, Volume 19, Issue 9, pp. 1247 - 1258
Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Ovarian Neoplasms - mortality | Protein Kinase Inhibitors - adverse effects | Angiogenesis Inhibitors - administration & dosage | Time Factors | Adult | Female | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Platinum Compounds - adverse effects | Sorafenib - administration & dosage | Double-Blind Method | Drug Administration Schedule | Topoisomerase I Inhibitors - administration & dosage | Topotecan - adverse effects | Sorafenib - adverse effects | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Topoisomerase I Inhibitors - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Topotecan - administration & dosage | Aged | Platinum Compounds - administration & dosage | Germany | Clinical trials | Analysis | Ovarian cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
by Michael A. Bookman and Mark F. Brady and William P. McGuire and Peter G. Harper and David S. Alberts and Michael Friedlander and Nicoletta Colombo and Jeffrey M. Fowler and Peter A. Argenta and Koen De Geest and David G. Mutch and Robert A. Burger and Ann Marie Swart and Edward L. Trimble and Chrisann Accario-Winslow and Lawrence M. Roth
Journal of clinical oncology, ISSN 0732-183X, 03/2009, Volume 27, Issue 9, pp. 1419 - 1425
Gynecology. Andrology. Obstetrics | Biological and medical sciences | Medical sciences | Tumors | Female genital diseases | Peritoneal Neoplasms - pathology | Deoxycytidine - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Carboplatin - administration & dosage | Polyethylene Glycols - administration & dosage | Disease-Free Survival | Peritoneal Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Doxorubicin - analogs & derivatives | Topotecan - administration & dosage | Female | Neoplasm Staging | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Doxorubicin - administration & dosage | Index Medicus | Original Reports | Gync19
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Topotecan–tamoxifen duple PLGA polymeric nanoparticles: Investigation of in vitro, in vivo and cellular uptake potential
by Khuroo, Tahir and Verma, Devina and Talegaonkar, Sushama and Padhi, Santwana and Panda, Amulya K and Iqbal, Zeenat
International journal of pharmaceutics, ISSN 0378-5173, 10/2014, Volume 473, Issue 1-2, pp. 384 - 394
Nanoparticles | P-glycoprotein | Topotecan | Bioavailability | Tamoxifen | MCF-7 | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Lactic Acid - chemistry | Nanoparticles - chemistry | Rats, Wistar | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Topoisomerase I Inhibitors - administration & dosage | Drug Carriers - administration & dosage | Tamoxifen - administration & dosage | Drug Carriers - chemistry | Intestinal Absorption | Topotecan - chemistry | Animals | Biological Transport | MCF-7 Cells | Polyglycolic Acid - chemistry | Tamoxifen - chemistry | Topotecan - administration & dosage | Female | Nanoparticles - administration & dosage | Antineoplastic Agents, Hormonal - chemistry | Lactic Acid - administration & dosage | Polyglycolic Acid - administration & dosage | Topoisomerase I Inhibitors - chemistry | Investigations | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer
by Stockler, Martin R and Stockler, Martin R and Hilpert, Felix and Hilpert, Felix and Friedlander, Michael and Friedlander, Michael and King, Madeleine T and King, Madeleine T and Wenzel, Lari and Wenzel, Lari and Lee, Chee Khoon and Lee, Chee Khoon and Joly, Florence and Joly, Florence and de Gregorio, Nikolaus and De Gregorio, Nikolaus and Arranz, José Angel and Arranz, José Angel and Mirza, Mansoor Raza and Mirza, Mansoor Raza and Sorio, Roberto and Sorio, Roberto and Freudensprung, Ulrich and Freudensprung, Ulrich and Sneller, Vesna and Sneller, Vesna and Hales, Gill and Hales, Gill and Pujade-Lauraine, Eric and Pujade-Lauraine, Eric
Journal of clinical oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1309 - 1316
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Female genital diseases | Doxorubicin - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Drug Resistance, Neoplasm | Polyethylene Glycols - therapeutic use | Organoplatinum Compounds - pharmacology | Bevacizumab | Antibodies, Monoclonal, Humanized - administration & dosage | Doxorubicin - analogs & derivatives | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Self Report | Paclitaxel - adverse effects | Topotecan - adverse effects | Treatment Outcome | Topotecan - therapeutic use | Paclitaxel - therapeutic use | Polyethylene Glycols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Aged | Doxorubicin - adverse effects | Index Medicus | Gync20 | Psc7 | Gync19 | ORIGINAL REPORTS | Psc13
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs
by Reddy, Joseph A and Dorton, Ryan and Bloomfield, Alicia and Nelson, Melissa and Vetzel, Marilynn and Guan, John and Leamon, Christopher P
Clinical cancer research, ISSN 1078-0432, 04/2014, Volume 20, Issue 8, pp. 2104 - 2114
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Folic Acid - pharmacology | Paclitaxel - pharmacology | Taxoids - pharmacology | Humans | Antineoplastic Agents - administration & dosage | Folic Acid - administration & dosage | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Neoplasms, Experimental - pathology | Vinca Alkaloids - administration & dosage | Vinca Alkaloids - pharmacology | Camptothecin - administration & dosage | Mice, Inbred DBA | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Folic Acid - analogs & derivatives | Topotecan - pharmacology | Carboplatin - administration & dosage | Treatment Outcome | Cisplatin - pharmacology | Neoplasms - drug therapy | Drug Synergism | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Topotecan - administration & dosage | Cell Proliferation - drug effects | Mice, Inbred BALB C | HeLa Cells | Carboplatin - pharmacology | Neoplasms - pathology | Camptothecin - pharmacology | Neoplasms, Experimental - drug therapy | Doxorubicin - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
by Ladenstein, Ruth, Prof and Pötschger, Ulrike, MSc and Pearson, Andrew D J, Prof and Brock, Penelope, MD and Luksch, Roberto, MD and Castel, Victoria, MD and Yaniv, Isaac, Prof and Papadakis, Vassilios, MD and Laureys, Geneviève, MD and Malis, Josef, MD and Balwierz, Walentyna, Prof and Ruud, Ellen, MD and Kogner, Per, Prof and Schroeder, Henrik, Prof and de Lacerda, Ana Forjaz, MD and Beck-Popovic, Maja, MD and Bician, Pavel, MD and Garami, Miklós, MD and Trahair, Toby, MD and Canete, Adela, MD and Ambros, Peter F, PhD and Holmes, Keith, MD and Gaze, Mark, MD and Schreier, Günter, PhD and Garaventa, Alberto, MD and Vassal, Gilles, Prof and Michon, Jean, MD and Valteau-Couanet, Dominique, MD and SIOP Europe Neuroblastoma Group (SIOPEN) and SIOP Europe Neuroblastoma Grp
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 500 - 514
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Follow-Up Studies | Humans | Bone Neoplasms - secondary | Carboplatin - administration & dosage | Child, Preschool | Etoposide - administration & dosage | Infant | Male | Survival Rate | Lymphatic Metastasis | Busulfan - administration & dosage | Young Adult | Melphalan - administration & dosage | International Agencies | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Adolescent | Adult | Female | Bone Neoplasms - drug therapy | Neoplasm Staging | Child | Neuroblastoma - pathology | Medical colleges | Chemotherapy | Stem cells | Etoposide | Dosage and administration | Product development | Busulfan | Research institutes | Neuroblastoma | Cancer | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights